Relypsa Given Average Rating of “Buy” by Brokerages (NASDAQ:RLYP)
Shares of Relypsa (NASDAQ:RLYP) have been given an average recommendation of “Buy” by the eight ratings firms that are currently covering the stock, AmericanBankingNews.com reports. Eight analysts have rated the stock with a buy recommendation, The average twelve-month target price among analysts that have issued a report on the stock in the last year is $48.50.
Relypsa (NASDAQ:RLYP) opened at 26.99 on Wednesday. Relypsa has a 52 week low of $11.55 and a 52 week high of $52.74. The stock’s 50-day moving average is $24.27 and its 200-day moving average is $28.43. The company’s market cap is $917.6 million.
Relypsa (NASDAQ:RLYP) last released its earnings data on Monday, August 11th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. On average, analysts predict that Relypsa will post $-2.47 earnings per share for the current fiscal year.
Separately, analysts at Stifel Nicolaus raised their price target on shares of Relypsa from $45.00 to $47.00 in a research note on Tuesday, August 12th. They now have a “buy” rating on the stock.
In other Relypsa news, Director Klaus R. Dr Veitinger sold 4,167 shares of Relypsa stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $27.73, for a total value of $115,550.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Relypsa, Inc is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.